Ravi A. Madan, M.D.

Ravi A. Madan, M.D.
Senior Clinician
Genitourinary Malignancies Branch
Clinical Director, Genitourinary Malignancies Branch

Dr. Madan is the clinical director of the Genitourinary Malignancies Branch. His clinical research is focused on immune stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune stimulating therapies can improve clinical outcomes and be combined with other therapies. In addition to investigating emerging therapeutics in all stages of prostate cancer, Dr. Madan is exploring immunotherapy treatment strategies in rare tumors such as medullary thyroid cancer.

Areas of Expertise

1) immunotherapy, 2) prostate cancer, 3) therapeutic cancer vaccines, 4) immune check point inhibitors, 5) metastatic prostate cancer, 6) medullary thyroid cancer

Contact Info

Ravi A. Madan, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 13N240B
Bethesda, MD 20892
Ph: 301-480-7168
Fax: 301-480-8867
madanr@mail.nih.gov
Get Vcard
View Dr. Madan's PubMed Summary.

Selected Publications

  1. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
    Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL.
    J Natl Cancer Inst. [Epub ahead of print], 2020. [ Journal Article ]
  2. How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer?.
    Karzai F, Madan RA, Dahut WL.
    Eur Urol. 77(1): 36-7, 2020. [ Journal Article ]
  3. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
    Rajan A, Heery CR, Thomas A, Mammen AL, Perry S, O'Sullivan Coyne G, Guha U, Berman A, Szabo E, Madan RA, Ballester LY, Pittaluga S, Donahue RN, Tsai YT, Lepone LM, Chin K, Ginty F, Sood A, Hewitt SM, Schlom J, Hassan R, Gulley JL.
    J Immunother Cancer. 7(1): 269, 2019. [ Journal Article ]
  4. Pembrolizumab: patient selection or immune intensification?.
    Madan RA, Gulley JL.
    Nat Rev Urol. 15(10): 593-4, 2018. [ Journal Article ]
  5. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
    Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL.
    Clin Cancer Res. 24(6): 1287-95, 2018. [ Journal Article ]

Dr. Madan is an Assistant Clinical Investigator at the National Cancer Institute (NCI), conducting clinical research in therapeutic cancer vaccines and genitourinary malignancies. Dr. Madan received his M.D. from the UMDNJ-New Jersey Medical School in 2001 and completed his internal medicine residency at UMDNJ-University Hospital in June 2004. He joined the NCI Medical Oncology Branch as an oncology/hematology fellow in 2005. He currently holds a joint appointment in the Medical Oncology Branch and the Laboratory of Tumor Immunology and Biology. His research interests are focused on immune stimulating therapeutic cancer vaccines and novel therapies in the treatment of prostate cancer.

Name Position
Philip Arlen M.D. Special Volunteer
Guinevere Chun Research Nurse
Carlos Diaz Patient Care Coordinator (Contr.)
Amy Hankin PA-C, MMSc Physician Assistant
Elizabeth Lamping R.N., B.S.N. Research Nurse
Sheri McMahon R.N., B.S.N. Research Nurse
Michelle Ojemuyiwa M.D. Clinical Collaborator
Helen Owens Research Nurse
Lee Pai-Scherf M.D. Clinical Collaborator
Myrna Rauckhorst R.N. Research Nurse
Moniquea Smith Patient Care Coordinator (Contr.)
Marc Theoret M.D. Clinical Collaborator
Monique Williams N.P. Nurse Practitioner (Contr.)
Search all
CCR clinical trials